Protein Supplementation to Promote Muscle Protein Anabolism in Frail Elderly People
Not Applicable
Completed
- Conditions
- Sarcopenia
- Registration Number
- NCT01109628
- Lead Sponsor
- Wageningen University
- Brief Summary
The present study is designed to investigate whether timed protein supplementation will increase skeletal muscle mass in the frail elderly population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
- Frail elderly individuals
- Able to understand and perform the study procedures
Exclusion Criteria
- Type I or type II diabetes (fasted blood glucose level ≥7,0 mmol)
- No recent history (within 2 years) of participating in any regular resistance exercise training program (general questionnaire)
- Use of anti-coagulation medication (except of Acetyl Salicyl acid)
- Renal insufficiency (eGFR <60 mL/min/1.73 m2)
- Allergic or sensitive for milk proteins
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in skeletal muscle mass Baseline, 3 months and 6 months
- Secondary Outcome Measures
Name Time Method Physical performance Baseline, 3 months and 6 months Blood parameters related to the outcome measures Baseline, 3 months and 6 months Dietary intake Baseline, 3 months and 6 months Blood pressure Baseline, 3 months and 6 months Physical activity Baseline, 3 months and 6 months Cognitive performance Baseline and 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie protein supplementation's effects on muscle protein anabolism in sarcopenia?
How does timed protein supplementation compare to standard-of-care interventions for frail elderly sarcopenia?
Which biomarkers correlate with increased skeletal muscle mass following protein supplementation in sarcopenic patients?
What adverse events are associated with high-dose protein supplementation in elderly populations and how are they managed?
Are there combination therapies involving protein supplementation that enhance muscle anabolism in sarcopenia compared to monotherapy?
Trial Locations
- Locations (1)
Wageningen University
🇳🇱Wageningen, Gelderland, Netherlands
Wageningen University🇳🇱Wageningen, Gelderland, Netherlands